NVN Liquidation, Inc.
NVN Liquidation, Inc. (NOVN): 4 pipeline candidates · ~14 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
13.7 months
D/E -29.22 · 0% dilution
Lead: Approved
4 candidates
N/A
N/A
A transparent, data-derived signal for NVN Liquidation, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$13.8M
Quarterly Burn
$4.3M
Runway
13.7 mo
Revenue
$3.2M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
Frequently asked questions
How many drug candidates are in NVN Liquidation, Inc.'s pipeline?
NVN Liquidation, Inc. (NOVN) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is NVN Liquidation, Inc.'s lead drug candidate?
NVN Liquidation, Inc.'s most advanced tracked candidate is lidocaine (Approved) for INDICATIONS AND USAGE Lidocaine is indicated for the production of topical anesthesia of irritated or inflamed mucous membranes of the mouth and pharynx. It is also useful for reducing gagging during the taking of X-ray pictures and dental impressions..
What is NVN Liquidation, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, NVN Liquidation, Inc. has approximately 13.7 months of cash runway.
Get the full picture on NVN Liquidation, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.